NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.04% | 14.25% | -3.25% | -13.20% | -16.87% |
| Depreciation & Amortization | 6,466.67% | 4,266.67% | 2,166.67% | 1,250.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.25% | 11.63% | -11.62% | -24.44% | -39.24% |
| Operating Income | -41.24% | 1.51% | 17.84% | 25.63% | 39.24% |
| Income Before Tax | 30.52% | -1.79% | -13.92% | -86.76% | -36.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.52% | -1.79% | -13.92% | -86.76% | -36.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.52% | -1.79% | -13.92% | -86.76% | -36.16% |
| EBIT | -41.24% | 1.51% | 17.84% | 25.63% | 39.24% |
| EBITDA | -39.98% | 2.14% | 18.09% | 25.67% | 39.25% |
| EPS Basic | 66.65% | 35.36% | 34.01% | -6.81% | 20.27% |
| Normalized Basic EPS | 53.68% | 43.03% | 43.86% | 25.85% | 34.95% |
| EPS Diluted | 66.65% | 35.36% | 34.01% | -6.81% | 20.27% |
| Normalized Diluted EPS | 53.68% | 43.03% | 43.86% | 25.85% | 34.95% |
| Average Basic Shares Outstanding | 110.47% | 102.29% | 100.81% | 79.17% | 61.55% |
| Average Diluted Shares Outstanding | 110.47% | 102.29% | 100.81% | 79.17% | 61.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |